SHR-4394

SHR-4394 is an antibody-drug conjugate (ADC) under development for the treatment of prostate cancer. It consists of an antibody coupled to the cytotoxic payload 9106-IM-2. The drug is being evaluated in Phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with prostate cancer. The developer and sponsor of these studies is Jiangsu Hengrui Pharmaceuticals (also known as Shanghai Hengrui Pharmaceutical or HengRui Medicine), a major Chinese pharmaceutical company[1][2][3][4]. As of early 2025, SHR-4394 remains in early-stage clinical development. The precise molecular target for the antibody component of SHR-4394 has not been disclosed in public sources as of April 2025. The drug's mechanism relies on targeted delivery of a cytotoxic agent via an antibody specific to a tumor-associated antigen; however, further details are pending publication from ongoing trials.